Welcome to our dedicated page for T2 Biosystems news (Ticker: TTOO), a resource for investors and traders seeking the latest updates and insights on T2 Biosystems stock.
T2 Biosystems, Inc. (Symbol: TTOO) is a pioneering company in the field of in vitro diagnostics, dedicated to improving patient health through advanced diagnostic products. The company’s core focus is on developing rapid diagnostic tools aimed at detecting sepsis-causing pathogens and antibiotic resistance genes. Sepsis, a condition that accounts for one out of two hospital deaths, is a primary target for T2 Biosystems.
Utilizing its proprietary T2 Magnetic Resonance platform, or T2MR®, the company has launched FDA-cleared products such as the T2Dx Instrument, T2Bacteria Panel, and T2Candida Panel. These products enable faster, more accurate detection of pathogens, allowing clinicians to make informed treatment decisions earlier. T2 Biosystems is also working on an array of other diagnostic solutions targeting hemostasis, bacteria, and Lyme disease. Notably, the T2Lyme Panel is slated for commercial launch in the third quarter of 2024.
Recent achievements highlight the company’s growth and stability. T2 Biosystems has recently achieved double-digit growth in sepsis product revenue and significantly reduced its total debt by approximately 80% over the past year. The company is a leader in the rapid detection of sepsis-causing pathogens, powered by its proprietary T2 Magnetic Resonance technology. These advancements not only promise to lower mortality rates but also aim to enhance patient outcomes and reduce healthcare costs.
T2 Biosystems is committed to fostering an innovative and inclusive work environment. The company actively seeks to attract and retain top talent, encouraging a culture of growth and excellence. For those interested in joining the mission to transform medical diagnostics, open positions can be found on their website.
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in rapid pathogen detection, announced the issuance of inducement awards to fourteen new employees on January 30, 2023. These awards, part of the company’s Inducement Award Plan, include thirteen option grants totaling 6,220 shares and one grant of restricted stock units (RSUs) covering 40,000 shares to VP Steve Miller. The options have an exercise price of $1.59, the closing price on the award date, and vest over four years. The award was approved by the independent compensation committee and aligns with Nasdaq Marketplace Rule 5635(c)(4).
T2 Biosystems, a leader in rapid detection of sepsis-causing pathogens, reported preliminary financial results for Q4 and full year 2022. Total revenue for 2022 reached $22.3 million, with product revenue at $11.3 million. The fourth quarter alone generated $5.5 million, including $2.2 million from product sales. The company achieved record sepsis product revenue and T2Dx Instrument contracts, with 51 units sold globally. Significant advancements included U.S. clinical trials for new panels and a FDA Breakthrough Device Designation for the T2Lyme Panel. Cash reserves were $11.9 million at year-end. Complete results will be available in March 2023.
T2 Biosystems, Inc. (NASDAQ:TTOO) announced the extension of its Innovative Technology contract with Vizient, Inc. until March 31, 2024. The contract continues to cover the T2Dx® Instrument and panels for detecting sepsis-causing pathogens from whole blood. This agreement enhances hospitals' access to T2 Biosystems' rapid diagnostic technologies, crucial for early targeted therapy for suspected sepsis patients. Vizient represents over $100 billion in combined purchasing volume annually, including more than 50% of acute care hospitals in the U.S.
On December 8, 2022, T2 Biosystems (NASDAQ:TTOO) announced the publication of a peer-reviewed article by Oxford University Press, emphasizing the critical need for early microbial diagnosis to combat sepsis. The article highlights that sepsis impacts approximately 50 million people globally each year, leading to substantial healthcare costs of about $62 billion in the U.S. alone. T2’s FDA-cleared instruments, including the T2Dx, T2Bacteria, and T2Candida Panels, aim to improve rapid diagnosis and treatment, aligning with CDC recommendations and addressing healthcare disparities in underserved communities.
T2 Biosystems, Inc. (NASDAQ:TTOO) reported third quarter 2022 revenues of $3.7 million, including $2.6 million in product revenue, with sepsis-related revenue reaching a record $2.4 million, up 24% year-over-year. The company executed contracts for 11 T2Dx® Instruments, increasing total units to 20 in the U.S. and 18 internationally. Key pipeline developments include a $3.7 million contract extension with BARDA for clinical trials and the FDA-designated breakthrough T2Lyme Panel. However, the net loss for Q3 2022 was $17.4 million, compared to $14.0 million in Q3 2021.
T2 Biosystems, Inc. (NASDAQ:TTOO) announced an amendment and extension of its Term Loan Agreement with CRG Servicing LLC, extending the maturity date to December 30, 2024. This amendment will provide additional balance sheet flexibility for the company. T2 Biosystems is noted for its rapid sepsis diagnostics, reporting record sepsis revenue in Q3 and ongoing pipeline development, including advancements in Lyme disease diagnostics. The partnership with CRG is critical for T2's ongoing growth strategy.
T2 Biosystems, a leader in sepsis detection, has announced its participation in the Canaccord Genuity MedTech Forum in New York. Scheduled for November 17, 2022, at 2 PM ET, the event will feature a presentation accessible via a live webcast on the company's website.
Known for its innovative T2 Magnetic Resonance technology, T2 Biosystems aims to enhance patient care by enabling faster treatment decisions. The firm offers various diagnostic panels, including T2Dx, T2Bacteria, T2Candida, T2Resistance, and T2SARS-CoV-2, and has several products in development.
T2 Biosystems (NASDAQ:TTOO) has been awarded $100,000 as a Phase 1 winner in the LymeX Diagnostics Prize, aimed at developing Lyme disease diagnostics. This funding supports the advancement of their T2Lyme Panel, designed for early detection of Lyme disease. The initiative encourages innovative solutions through no-strings-attached funding and collaboration opportunities. In future phases, the focus will shift to clinical validation and regulatory submission processes. The T2Lyme Panel recently received FDA Breakthrough Device Designation and a patent.
T2 Biosystems (NASDAQ:TTOO) announced on November 1, 2022, that it has regained compliance with NASDAQ's minimum bid price requirement after being notified in November 2021 of non-compliance. The company maintained a closing bid price above $1.00 for ten consecutive trading days, achieving the necessary compliance status on October 26, 2022. T2 Biosystems specializes in rapid detection of sepsis-causing pathogens and antibiotic resistance genes, offering various diagnostic panels powered by its proprietary technology.
T2 Biosystems (NASDAQ:TTOO) announced it will release its third quarter 2022 financial results on November 10, 2022, after market close. A conference call will follow at 4:30 p.m. ET, which investors can access via a live and archived webcast on the company’s website. T2 Biosystems specializes in rapid detection of sepsis-causing pathogens and antibiotic resistance genes, with products like the T2Dx® Instrument and various panels powered by their proprietary T2 Magnetic Resonance (T2MR®) technology. The company aims to enhance patient care and reduce costs.
FAQ
What is the current stock price of T2 Biosystems (TTOO)?
What is the market cap of T2 Biosystems (TTOO)?
What is T2 Biosystems, Inc. known for?
What are the core products of T2 Biosystems?
What proprietary technology does T2 Biosystems use?
What recent financial achievements has T2 Biosystems made?
When is the T2Lyme Panel expected to launch?
Where can I find job opportunities at T2 Biosystems?
How does T2 Biosystems aim to impact healthcare?
Who can I contact for investor-related inquiries?
What areas of unmet medical need is T2 Biosystems targeting?
How does T2MR® technology benefit patient care?
